FDA Approves Keytruda for Early-Stage Triple-Negative Breast Cancer July 27, 2021 The U.S. Food and Drug Administration (FDA) has approved Keytruda plus chemotherapy before surgery, followed by Keytruda alone after surgery to treat early-stage triple-negative breast cancer with a high risk of recurrence. Read more...
